Sangamo’s Gene Therapy for Hunter Syndrome Gets FDA Orphan Designation – Rare Disease Report
|
Sangamo’s Gene Therapy for Hunter Syndrome Gets FDA Orphan Designation
Rare Disease Report SB-913 is a type of gene therapy that uses Sangamo’s zinc finger nuclease (ZFN) genome editing technology to provide stable, continuous production of iduronate 2-sulfatase for the lifetime of the patient. Hunter syndrome is due to low levels of … |
Medical Xpress |
Absent tumor-suppressors allow melanoma to thwart immunotherapy
Medical Xpress Researchers identified a set of genetic changes that predict whether melanoma patients will respond to checkpoint inhibitor therapies. Credit: Chris Bickel / Science Translational Medicine (2017). It’s what’s missing in the tumor genome, not what’s … |
Xconomy |
Join Xconomy in June for ‘What’s Hot In Cancer Immunotherapy 2017′
Xconomy Our bodies fight cancer every day, repairing DNA and cleaning out suspicious cells. But sometimes our powerful immune systems need help. That’s the concept of immunotherapy. Three years ago, the ideas long dreamed of by cancer researchers were … |
|
Round one of the the US CRISPR patent battle is over – but what does the PTABS’s no interference-in-fact decision …
Lexology (registration) [1] These proceedings are part of a wider dispute over the ownership of the patent rights to the fundamental components of the CRISPR/Cas9 system currently taking place in the U.S. and Europe between UCB, the Broad and others. …. fact that they … |
|
Round one of the the US CRISPR patent battle is over – but what does the PTABS’s no interference-in-fact decision …
Lexology (registration) [1] These proceedings are part of a wider dispute over the ownership of the patent rights to the fundamental components of the CRISPR/Cas9 system currently taking place in the U.S. and Europe between UCB, the Broad and others. …. fact that they … |